This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Prostatic Neoplasm, Genital Neoplasms, Male, Neoplasms, Abdominal, Urogenital Neoplasms, Genital Diseases, Male, Prostatic Diseases, Antineoplastic Agents or Imatinib
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

Provided treatments

  • Drug: STI571 (Glivec®)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01316458. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 51 volunteers for the current phase.
Official trial title:
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy